Cartesian Therapeutics (RNAC) Non-Current Assets (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Non-Current Assets of $166.4 million for Q1 2026, down 25.74% year-over-year from $224.0 million in Q1 2025, and little changed quarter-over-quarter from $167.1 million in Q4 2025.
Cartesian Therapeutics (RNAC) Non-Current Assets (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Non-Current Assets for 12 consecutive years, with $166.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 25.74% year-over-year to $166.4 million; the TTM figure through Mar 2026 stood at $784.4 million (down 12.02% YoY), while the FY2025 annual figure was $167.1 million, down 23.47% from the prior year.
- Non-Current Assets steadied at $166.4 million in Q1 2026 per RNAC's latest filing, from $167.1 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $226.2 million in Q3 2024 and bottomed at $15.5 million in Q2 2022.
- Historically, Non-Current Assets has averaged $130.7 million across 5 years, with a median of $167.1 million in 2025.
- Annual changes were most pronounced in 2024 — Non-Current Assets surged 1299.2% — and 2026, when it decreased 25.74%.
- Cartesian Therapeutics' Non-Current Assets stood at $17.7 million in 2022, then soared by 1107.58% to $214.3 million in 2023, then gained by 1.9% to $218.4 million in 2024, then slipped by 23.47% to $167.1 million in 2025, then retreated by 0.47% to $166.4 million in 2026.
- Business Quant data shows RNAC's Non-Current Assets at $166.4 million in Q1 2026, $167.1 million in Q4 2025, and $225.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | 165.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 165.01 Mn |
| Mar 31, 2026 | 166.35 Mn |
| Dec 31, 2025 | 167.14 Mn |
| Sep 30, 2025 | 225.42 Mn |
| Jun 30, 2025 | 225.50 Mn |
| Mar 31, 2025 | 224.01 Mn |
| Dec 31, 2024 | 218.40 Mn |
| Sep 30, 2024 | 226.18 Mn |
| Jun 30, 2024 | 222.96 Mn |
| Mar 31, 2024 | 214.10 Mn |
| Dec 31, 2023 | 214.32 Mn |
| Sep 30, 2023 | 16.17 Mn |
| Jun 30, 2023 | 16.78 Mn |
| Mar 31, 2023 | 17.30 Mn |
| Dec 31, 2022 | 17.75 Mn |
| Sep 30, 2022 | 18.59 Mn |
| Jun 30, 2022 | 15.50 Mn |
| Mar 31, 2022 | 15.69 Mn |
| Dec 31, 2021 | 15.44 Mn |
| Sep 30, 2021 | 15.39 Mn |